Longwood Capital Partners »

Design Therapeutics shares owned by Longwood Capital Partners

Quarter-by-quarter ownership of Design Therapeutics (DSGN) shares owned by Longwood Capital Partners from 13F filings

Historical chart of Longwood Capital Partners investment in Design Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Design Therapeutics held by Longwood Capital Partners consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Design Therapeutics by Longwood Capital Partners

Quarter filed Position value Share count Share price at filing
2025-12-31 $1.4M 151k 9.38

More positions owned by Longwood Capital Partners

Terns Pharmaceuticals (TERN)
Praxis Precision Medicines I (PRAX)
Cidara Therapeutics Com New (CDTX)
Ocular Therapeutix (OCUL)
Aadi Bioscience (WHWK)
Bright Minds Biosciences Com New (DRUG)
Compass Therapeutics (CMPX)
Jazz Pharmaceuticals Shs Usd (JAZZ)
Insmed Com Par $.01 (INSM)
Argen Se - Sponsored Adr (ARGX)
Surrozen Com New (SRZN)
Amylyx Pharmaceuticals (AMLX)
Minerva Neurosciences Com New (NERV)
Tango Therapeutics (TNGX)
Taysha Gene Therapies Com Shs (TSHA)

View all positions for Longwood Capital Partners

Top funds holding Design Therapeutics

Sr One Capital Management
Point72 Asset Management
Logos Global Management
BlackRock
Baker Bros. Advisors
Vanguard Group
Vivo Capital
Almitas Capital
Driehaus Capital Management
Woodline Partners
Kynam Capital Management
FMR
Geode Capital Management
State Street Corporation
Acadian Asset Management

View all funds holding Design Therapeutics